Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, May 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 3 X users

reddit: 1 Redditor

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 63 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 9 X posts from 3 X users, with an upper bound of 2,259 followers.

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor ... https://t.co/HXiLwrT6KJ

23 Nov 2021

Reply Repost Favourite

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor ... https://t.co/HXiLwrT6KJ

20 Aug 2021

Reply Repost Favourite

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor ... https://t.co/HXiLwrT6KJ

27 Jun 2021

Reply Repost Favourite

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC https://t.co/HXiLwrT6KJ

24 Mar 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.